Program of Cardiovascular Diseases, Centre for Applied Medical Research, University of Navarra, Pamplona, Spain; CIBERCV (Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares), Carlos III Institute of Health, Madrid, Spain.
Department of Medicine, Heart and Vascular Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
J Am Coll Cardiol. 2018 Apr 17;71(15):1696-1706. doi: 10.1016/j.jacc.2018.02.021.
Myocardial interstitial fibrosis contributes to left ventricular dysfunction leading to the development of heart failure. Basic research has provided abundant evidence for the cellular and molecular mechanisms behind this lesion and the pathways by which it imparts a detrimental impact on cardiac function. Translation of this knowledge, however, to improved diagnostics and therapeutics for patients with heart failure has not been as robust. This is partly related to the paucity of biomarkers to accurately identify myocardial interstitial fibrosis and to the lack of personalized antifibrotic strategies to treat it in an effective manner. This paper summarizes current knowledge of the mechanisms and detrimental consequences of myocardial interstitial fibrosis, discusses the potential of circulating and imaging biomarkers available to recognize different phenotypes of this lesion and track their clinical evolution, and reviews the currently available and potential future therapies that allow its individualized management in heart failure patients.
心肌间质纤维化导致左心室功能障碍,进而导致心力衰竭的发生。基础研究为这一病变背后的细胞和分子机制以及它对心脏功能产生不利影响的途径提供了丰富的证据。然而,将这些知识转化为改善心力衰竭患者的诊断和治疗方法的效果并不显著。这在一定程度上与缺乏准确识别心肌间质纤维化的生物标志物以及缺乏有效的个性化抗纤维化策略有关。本文总结了心肌间质纤维化的机制和有害后果的现有知识,讨论了现有的循环和影像学生物标志物用于识别这种病变的不同表型及其临床演变的潜力,并回顾了目前可用的和潜在的未来治疗方法,这些方法可以实现心力衰竭患者的个体化管理。